Business
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The collaboration for development and commercialization combines Esperion’s knowledge in lipid management and Otsuka’s extensive cardiovascular drug advancement and marketing in Japan.
Relmada Therapeutics is working to develop a treatment, REL-1017, for those with depression that do not respond to drugs currently on the market.
At least some of the concern is that without greater funding and coordination, the companies won’t be able to buy sufficient raw materials, continue production of existing drugs and quickly scale up their capacity to meet the demand of new drugs and older therapies around the world.
The Rockefeller Foundation laid out its COVID-19 Testing Action Plan as a fundamental step to reopen the country.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 21, 2020.
CEVEC Pharmaceuticals GmbH announced the signing of a license agreement with Evox Therapeutics, Ltd. for the development and commercialization of therapeutic exosomes using CEVEC’s proprietary CAP® technology.
Traditional vaccine development and regulatory policies are changing in response to the current pandemic. Some of those approaches may become more common, expanding into other, non-pandemic-related areas in the future.
GlobalData released a report that showed the global healthcare sector has been subjected to an array of cyberattacks as it deals with the COVID-19 pandemic.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 20, 2020.
Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have.